Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Selective elimination of BRCA1-deficient cells by inhibitors of poly(ADP-ribose) polymerase (PARP) is a prime example of the concept of synthetic lethality in cancer therapy. This interaction is counteracted by the restoration of BRCA1-independent homologous recombination through loss of factors such as 53BP1, RIF1, and REV7/MAD2L2, which inhibit end resection of DNA double-strand breaks (DSBs). To identify additional factors involved in this process, we performed CRISPR/SpCas9-based loss-of-function screens and selected for factors that confer PARP inhibitor (PARPi) resistance in BRCA1-deficient cells. Loss of members of the CTC1-STN1-TEN1 (CST) complex were found to cause PARPi resistance in BRCA1-deficient cells in vitro and in vivo. We show that CTC1 depletion results in the restoration of end resection and that the CST complex may act downstream of 53BP1/RIF1. These data suggest that, in addition to its role in protecting telomeres, the CST complex also contributes to protecting DSBs from end resection.

Original publication

DOI

10.1016/j.celrep.2018.04.046

Type

Journal article

Journal

Cell Rep

Publication Date

15/05/2018

Volume

23

Pages

2107 - 2118

Keywords

BRCA1, CST complex, CTC1, DNA end resection, PARP inhibitor, STN1, TEN1, breast cancer, drug resistance, genetically engineered mouse model, Animals, BRCA1 Protein, CRISPR-Cas Systems, Cell Line, Tumor, DNA Breaks, Double-Stranded, Disease Models, Animal, Drug Resistance, Neoplasm, Female, Mice, Mouse Embryonic Stem Cells, Multiprotein Complexes, Poly(ADP-ribose) Polymerase Inhibitors, Telomere